A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...

Ultimately, the collaboration is focused on speeding up progress toward a safer and more resilient food system. As Corbion's ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

The news for the chocolate industry is a welcome development, as businesses and scientists grapple with crop shortages.

Martin Kampmann’s work, supported by the National Institutes of Science (NIH), maps cellular “decision points” that determine ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...